Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - PDL BIOPHARMA, INC. | pdl_8k-031412.htm |
Exhibit 99.1
Contacts:
|
John McLaughlin
PDL BioPharma, Inc.
775-832-8500
john.mclaughlin@pdl.com
|
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org
|
PDL BioPharma Completes Regular Quarterly Dividend Payment
INCLINE VILLAGE, NV, March 14, 2012 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 7, 2012, the record date.
About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.
# # #